| Literature DB >> 28331816 |
Katharina Stoecker1, Steffen Sass2, Fabian J Theis3, Hans Hauner4, Michael W Pfaffl1.
Abstract
The process of adipogenesis is controlled in a highly orchestrated manner, including transcriptional and post-transcriptional events. In developing 3T3-L1 pre-adipocytes, this program can be interrupted by all-trans retinoic acid (ATRA). To examine this inhibiting impact by ATRA, we generated large-scale transcriptomic data on the microRNA and mRNA level. Non-coding RNAs such as microRNAs represent a field in RNA turnover, which is very important for understanding the regulation of mRNA gene expression. High throughput mRNA and microRNA expression profiling was performed using mRNA hybridisation microarray technology and multiplexed expression assay for microRNA quantification. After quantitative measurements we merged expression data sets, integrated the results and analysed the molecular regulation of in vitro adipogenesis. For this purpose, we applied local enrichment analysis on the integrative microRNA-mRNA network determined by a linear regression approach. This approach includes the target predictions of TargetScan Mouse 5.2 and 23 pre-selected, significantly regulated microRNAs as well as Affymetrix microarray mRNA data. We found that the cellular lipid metabolism is negatively affected by ATRA. Furthermore, we were able to show that microRNA 27a and/or microRNA 96 are important regulators of gap junction signalling, the rearrangement of the actin cytoskeleton as well as the citric acid cycle, which represent the most affected pathways with regard to inhibitory effects of ATRA in 3T3-L1 preadipocytes. In conclusion, the experimental workflow and the integrative microRNA-mRNA data analysis shown in this study represent a possibility for illustrating interactions in highly orchestrated biological processes. Further the applied global microRNA-mRNA interaction network may also be used for the pre-selection of potential new biomarkers with regard to obesity or for the identification of new pharmaceutical targets.Entities:
Keywords: 3T3-L1 cells; Adipogenesis; All-trans retinoic acid (ATRA); MicroRNA–mRNA interaction; Multiple linear regression models; Regulation of biological pathways
Year: 2016 PMID: 28331816 PMCID: PMC5348118 DOI: 10.1016/j.bdq.2016.11.001
Source DB: PubMed Journal: Biomol Detect Quantif
Fig. 1ATRA modulates the phenotype as well as the post-transcriptional mechanisms in 3T3-L1 cells. (A) Oil-red-O-staining of 3T3-L1 cells: Quantification of lipid accumulation in DMI-treated (control) and DMI + 3 μM ATRA-treated 3T3-L1 cells. After the indicated times, DMI (±3 μM ATRA) was replaced by growth medium without ATRA. Only in the labelled 96-h approach, DMI + 3 μM ATRA was changed to growth medium with ATRA for 288 h (12 d). (B) 3T3-L1 cell phenotypes: lipid accumulation in ATRA-treated and -untreated cells were visualised by microscopic images. (C) Relative gene expression trend, either up- or down-regulated, in the control and ATRA-treated cells in the time frame 2 h to 96 h (compared with 0 h). (D) MicroRNA expression profiling: Expression changes in ATRA-untreated 3T3-L1 cells are presented relative to 0 h, whereas the expression changes in ATRA-treated 3T3-L1 cells are presented relative to the corresponding untreated samples. An increase in microRNA expression is represented by accelerating red intensities, whereas decreasing ratios are represented by accelerating green intensities.
Changes in microRNA expression in DMI-treated 3T3-L1 cells.
| microRNA | 0 h DMI | 2 h DMI | 4 h DMI | 7 h DMI | 10 h DMI | 24 h DMI | 48 h DMI | 96 h DMI | 12d DMI |
|---|---|---|---|---|---|---|---|---|---|
| miR-99a | 0 | 0,1 | 0,1 | 0,1 | −0,1 | −0,4 | −0,3 | 1,1 | 1,5 |
| miR-96 | 0 | 0 | 0,2 | 0 | −0,1 | −0,4 | −0,7 | −0,8 | 2,6 |
| miR-93 | 0 | 0 | 0,1 | 0,2 | 0,3 | 0,9 | 0,6 | 0,2 | 0,2 |
| miR-365 | 0 | 0,2 | 0,3 | 0,2 | 0,2 | 0,3 | −0,1 | 0,6 | 2,3 |
| miR-29b | 0 | −0,1 | 0,2 | 0,3 | 0,4 | −0,3 | −0,3 | −1,1 | −2 |
| miR-29a | 0 | 0 | 0,3 | 0,3 | 0,3 | −0,1 | −0,5 | −1,1 | −1,9 |
| miR-27a | 0 | 0,1 | 0,2 | 0,3 | 0 | −0,2 | 0,2 | 0 | −0,4 |
| miR-23b | 0 | 0 | 0,1 | 0 | 0,1 | 0,1 | 0,1 | 0,3 | −0,4 |
| miR-221 | 0 | −0,1 | −0,2 | −0,3 | −0,4 | −0,9 | −1,7 | −1,7 | −2,7 |
| miR-218 | 0 | 0 | −0,2 | −0,3 | 0,1 | −0,5 | −0,1 | −0,5 | −1,5 |
| miR-210 | 0 | −0,3 | −0,4 | −0,4 | 0,1 | 0,3 | 0,6 | −0,1 | 2,4 |
| miR-21 | 0 | 0 | 0,1 | 0 | 0,1 | −0,2 | 0 | 0 | −1,6 |
| miR-20a/20b | 0 | 0 | 0,2 | 0,4 | 0,3 | 0,6 | 0,3 | 0,1 | −1,1 |
| miR-199a-5p | 0 | 0,1 | −0,1 | −0,3 | −0,2 | −0,4 | −0,1 | −0,3 | −1,3 |
| miR-199a-3p | 0 | 0,1 | 0,2 | 0,1 | −0,1 | −0,2 | −0,2 | −0,1 | −1,2 |
| miR-193 | 0 | 0 | −0,2 | 0 | 0,1 | −0,7 | −0,5 | 0,6 | 2,3 |
| miR-148a | 0 | 0,1 | 0 | −0,2 | 0 | −0,6 | −0,5 | 0,7 | 2,9 |
| miR-146b | 0 | −0,1 | 0,1 | 0 | 0,4 | 0,2 | 0,4 | 0,8 | 1,3 |
| miR-125b-5p | 0 | 0,1 | 0,1 | 0 | 0 | −0,2 | −1 | −1 | −1,4 |
| miR-125a-5p | 0 | 0,2 | 0,1 | 0 | −0,2 | 0 | −0,4 | −0,2 | −0,6 |
| miR-10b | 0 | −0,1 | −0,2 | −0,4 | −0,3 | −0,5 | 0 | 0,8 | 0,7 |
| miR-103 | 0 | 0,2 | 0,2 | 0,2 | 0,3 | 0,4 | 0,8 | 1,8 | 3,2 |
| miR-100 | 0 | 0,2 | 0 | 0,1 | 0 | 0 | −0,7 | −0,5 | −0,2 |
Fold changes are presented relative to 0 h (log2-transformed ratios).
Changes in microRNA expression in 3 μM ATRA-treated 3T3-L1 cells.
| microRNA | 0 h ATRA | 2 h ATRA | 4 h ATRA | 7 h ATRA | 10 h ATRA | 24 h ATRA | 48 h ATRA | 96 h ATRA | 12d ATRA |
|---|---|---|---|---|---|---|---|---|---|
| miR-99a | 0 | 0 | 0 | −0,2 | −0,1 | 0 | 0,1 | −0,3 | 0,4 |
| miR-96 | 0 | 0,2 | −0,1 | 0,1 | 0,1 | 0,2 | 0,3 | 0,7 | −2,8 |
| miR-93 | 0 | 0 | −0,1 | −0,2 | −0,2 | −0,3 | 0,4 | 0,2 | −0,8 |
| miR-365 | 0 | −0,1 | 0,1 | 0 | 0 | −0,3 | 0,3 | −0,7 | −2,1 |
| miR-29b | 0 | 0,2 | 0 | 0,1 | 0,1 | 0,5 | 0,3 | 0,6 | 0 |
| miR-29a | 0 | 0 | −0,1 | 0,1 | 0,2 | 0,2 | 0,5 | 0,6 | 0,7 |
| miR-27a | 0 | 0,1 | −0,2 | −0,2 | 0 | −0,5 | −0,9 | −1 | 0 |
| miR-23b | 0 | 0 | −0,1 | 0 | 0,2 | 0 | 0,3 | 0 | 0,4 |
| miR-221 | 0 | 0,1 | 0,1 | 0,1 | 0,1 | 0,2 | 0,2 | 0,6 | 1,6 |
| miR-218 | 0 | 0,1 | 0,2 | 0,3 | 0 | 0,3 | −0,6 | −0,4 | 0,7 |
| miR-210 | 0 | 0,1 | 0,1 | 0 | −0,1 | 0,3 | 0,4 | −0,1 | −2,9 |
| miR-21 | 0 | 0 | −0,1 | 0 | 0 | 0,2 | −0,1 | −0,1 | 0,5 |
| miR-20a/20b | 0 | 0 | −0,1 | −0,2 | −0,2 | −0,3 | −0,2 | −0,8 | −0,5 |
| miR-199a-5p | 0 | 0 | 0,1 | 0,2 | 0,1 | 0 | 0,1 | 0,3 | 1,1 |
| miR-199a-3p | 0 | 0 | 0 | 0 | 0,3 | 0 | −0,1 | −0,1 | 1,1 |
| miR-193 | 0 | 0,3 | 0,3 | 0 | 0,1 | 0,7 | −0,4 | −1,2 | −2,3 |
| miR-148a | 0 | 0,2 | 0,1 | 0,2 | 0 | 0,3 | 0,2 | −0,6 | −2,4 |
| miR-146b | 0 | 0,2 | −0,1 | 0 | −0,3 | −0,1 | −0,2 | −1,1 | −2,1 |
| miR-125b-5p | 0 | 0 | 0 | 0 | 0,2 | 0 | 0,6 | 0,2 | 1 |
| miR-125a-5p | 0 | −0,2 | −0,1 | 0 | 0,2 | −0,2 | 0,5 | 0,4 | 1 |
| miR-10b | 0 | 0,1 | 0,2 | 0,2 | 0 | 0 | −0,7 | −0,6 | 0,1 |
| miR-103 | 0 | 0,2 | 0,1 | 0 | 0 | 0 | 0,2 | −0,6 | −1,6 |
| miR-100 | 0 | 0 | 0 | −0,1 | 0,3 | 0,1 | 0,7 | 0,6 | 0,9 |
Fold changes are presented relative to the corresponding untreated samples (log2-transformed ratio).
Fig. 2Quantitative analysis of mRNA expression by RT-qPCR of adipogenetic specific regulators in DMI-treated (red) and DMI + 3 μM ATRA-treated (blue) preadipocytes in a time course study (0–288 h). ATRA has no effect on the gene expression of (A) Cebpβ, whereas the expression of (B) Cebpα (C) Pparγ (D) Srebf1 (E) Rxrα is inhibited by ATRA. Expression changes are presented relative to 0 h.
Fig. 3Regulation of biological processes in DMI-treated and DMI + 3 μM ATRA-treated 3T3-L1 cells. (A) Regulated GO terms in DMI and ATRA treated 3T3-L1 cells in early stages (2, 4 and 7 h post-induction) and mid stages of differentiation (10 and 24 h), ATRA (blue) only has small effects on biological processes compared with DMI treatment (red). (B) Cluster of ATRA regulated GO terms in the late stages of early differentiation (48/96 h post-induction). GO terms were analysed by the Genomatix Software and the top 50 regulated GO terms per time were selected and visualised with Revigo. The late regulation (48 and 96 h) of GO terms is visualised. The cellular lipid metabolism is most affected by ATRA, shown in the left yellow supercluster. The size of the rectangles represents the level of significance, whereby the log10 p-values of the GO term enrichments are given at the bottom.
Changes in mRNA expression in ATRA-treated 3T3-L1 cells.
| Gene name | Gene description | 2h | 4h | 7h | 10h | 24h | 48h | 96h |
|---|---|---|---|---|---|---|---|---|
| acyl-Coenzyme A dehydrogenase, medium chain | 0,1 | 0,3 | −0,1 | 0,1 | −0,3 | −1,1 | −1,4 | |
| acetyl-Coenzyme A acyltransferase 2 | 0,2 | 0,6 | 1 | 0,9 | 0,7 | 0,3 | −0,3 | |
| 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 | 0,5 | 1 | 1,2 | 0,9 | 1,2 | 0,7 | 0,8 | |
| phosphofructokinase, platelet | 0 | −0,1 | −0,2 | −0,3 | −0,1 | −1,4 | −1,8 | |
| glucose phosphate isomerase 1 | 0,4 | 0,7 | 0,7 | 0,5 | 0,9 | 1 | 0,8 | |
| malate dehydrogenase 1, NAD (soluble) | −0,1 | 0,2 | 0 | 0,1 | 0,1 | −0,4 | −1,2 | |
| pyruvate carboxylase | 0,1 | 0,2 | 0 | 0,8 | 1 | 0 | −0,5 | |
| dihydrolipoamide S-acetyltransferase (E2 component of pyruvate dehydrogenase complex) | 0 | 0 | 0 | 0,1 | 0,1 | −0,3 | −0,9 | |
| pyruvate dehydrogenase kinase, isoenzyme 4 | 1 | 1,1 | 0,2 | 1,4 | 0,6 | 0,6 | −0,2 | |
| aconitase 1 | 0,1 | 0,1 | 0,1 | 0 | −0,1 | −0,3 | −1,2 | |
| isocitrate dehydrogenase 3 (NAD+) alpha | 0,1 | 0,2 | 0,1 | 0 | 0,7 | 0,1 | −1,3 | |
| isocitrate dehydrogenase 2 (NADP+), mitochondrial | 0 | 0 | −0,4 | −0,1 | −0,6 | −1,2 | −0,6 | |
| fatty acid synthase | 0,1 | −0,1 | 0 | 0 | 0,1 | −0,3 | −1,3 | |
| stearoyl-Coenzyme A desaturase 1 | 1,2 | 1,3 | 1 | 0,5 | 1,5 | 0,2 | −0,8 | |
| acyl-CoA synthetase long-chain family member 1 | 0 | −0,4 | −0,2 | −0,4 | −0,4 | −2,5 | −3,3 | |
| acyl-CoA synthetase long-chain family member 4 | 0,4 | 0 | 0,4 | 0 | 0,6 | 1,1 | 1,6 | |
| fatty acid binding protein 4, adipocyte | −0,1 | 0 | 0,5 | 0,3 | 0,8 | −0,6 | −1,3 | |
| fatty acid binding protein 5, epidermal | −0,3 | 0 | 0,2 | 0,4 | 0,5 | −0,5 | −1,3 | |
| 1-acylglycerol-3-phosphate | 0,1 | −0,4 | −0,4 | −0,3 | −0,7 | −1,7 | −2,9 | |
| lipin 1 | 0 | 0,3 | −0,2 | 0 | −0,1 | −1,3 | −1,8 | |
| diacylglycerol | 0,5 | 0,9 | 0,4 | 0,1 | −0,1 | −1,7 | −2,4 | |
| diacylglycerol | 0 | 0,1 | 0,1 | 0 | −0,2 | −1,6 | −2,5 | |
| perilipin | −0,1 | 0 | 0,1 | 0 | 0,1 | 0,1 | −1,4 | |
| lipase, hormone sensitive | 0,1 | 0,2 | −0,3 | 0 | −0,2 | −1,5 | −2,6 | |
| lipoprotein lipase | 0 | −0,1 | 0,1 | 0,5 | 1,1 | 0,7 | −0,2 | |
| patatin-like phospholipase domain containing 2 | 0,1 | 0 | −0,1 | 0,1 | −0,5 | −2,7 | −2,5 | |
| platelet derived growth factor receptor, alpha polypeptide | 0,3 | 1,3 | 1 | 1,5 | 1,5 | 2 | 2,1 | |
| adenylate cyclase 6 | 0,2 | 0,3 | 0 | 0,3 | 0,6 | 0,7 | 0,9 | |
| Son of sevenless homolog 1 (Drosophila) | 0,1 | 0 | 0,2 | 0,1 | 0,1 | 0,4 | 0,3 | |
| muscle and microspikes RAS | 0 | −0,1 | −0,2 | 0,1 | −0,1 | −0,9 | −0,7 | |
| vav 3 oncogene | 0,1 | −0,1 | 0,1 | 0,3 | 0,1 | 0,2 | 0,7 | |
| p21 (CDKN1A)-activated kinase 3 | 0 | −0,3 | −0,2 | 0,2 | 0,1 | 0,2 | 1 | |
| WAS protein family, member 2 | 0 | −0,2 | −0,4 | 0,1 | −0,1 | −0,4 | −0,2 | |
| LIM motif-containing protein kinase 2 | 0,2 | 0,4 | 0,2 | 0,1 | 0,4 | 1,1 | 0,7 | |
| Actin related protein 2/3 | 0 | 0 | −0,2 | −0,1 | −0,2 | −0,1 | −0,5 |
Fold changes are presented relative to the corresponding untreated samples (log2-transformed ratios).
Fig. 4Schematic overview of metabolic processes that are affected by ATRA during adipogenesis in 3T3-L1 cells over 96 h. The highlighted genes are direct targets of Pparγ. Gene expression changes in ATRA-treated 3T3-L1 cells are presented relative to the corresponding untreated samples. The colour code reflects an up- or down-regulation greater than 1.5.
Fig. 5Joint analysis of real microRNA and mRNA data on the basis of target prediction of TargetScan Mouse 5.2 [44] and a linear regression model [49]. The edges in the network correspond to an association of the microRNA to the gene sequence and its expression level. The edge weights denote the anti-correlation (=the negative coefficient of the respective microRNA-mRNA relation in the multiple regression model).
Fig. 6Overview of the most significantly regulated KEGG pathways in ATRA-treated 3T3-L1 cells after in silico-based joint analysis of microRNA and mRNA data with the corresponding expression data over time and treatment. Expression changes of the ATRA-treated 3T3-L1 cells are presented relative to the corresponding untreated samples. The colour code reflects a regulation greater than 1.5. (A) Gap junction, (B) regulation of actin cytoskeleton, (C) TCA cycle. (For the whole network, see electronic supplementary S5–S7 Figures).
Changes in mRNA expression in DMI-treated 3T3-L1 cells.
| Gene name | Gene description | 2h | 4h | 7h | 10h | 24h | 48h | 96h |
|---|---|---|---|---|---|---|---|---|
| pyruvate carboxylase | −0,1 | −0,2 | −0,4 | −0,4 | 0,8 | 2,6 | 3,2 | |
| dihydrolipoamide | 0 | 0 | 0 | −0,1 | 0,4 | 0,7 | 1,5 | |
| platelet derived growth factor receptor, alpha polypeptide | −1,5 | −2,8 | −2,7 | −2,1 | −2,1 | −2,4 | −2,8 | |
| adenylate cyclase 6 | −0,6 | −0,7 | −0,5 | −0,7 | −0,6 | 0 | −0,1 | |
| Son of sevenless homolog 1 (Drosophila) | −0,4 | −0,4 | −0,1 | 0 | 0 | −0,1 | 0,2 | |
| muscle and microspikes RAS | 0 | −0,5 | −0,6 | −0,4 | −0,2 | 0,7 | 0,5 | |
| vav 3 oncogene | 0 | −0,1 | −0,2 | −0,1 | −0,1 | 0,1 | 0 | |
| p21 (CDKN1A)-activated kinase 3 | 0,3 | −0,2 | −0,7 | −0,9 | −0,5 | −0,3 | −0,9 | |
| WAS protein family, member 2 | −0,2 | −0,7 | −0,8 | −0,8 | −0,3 | 0,1 | 0 | |
| LIM motif-containing protein kinase 2 | −0,1 | 0,1 | 0,1 | 0 | 0,1 | 0,7 | 1,4 | |
| Actin related protein 2/3 | −0,1 | 0,1 | 0,3 | 0,5 | 0,8 | 0,5 | 1 |
Fold changes are presented relative to 0 h (log2-transformed ratios).